Richard Jacobs

Richard F Jacobs, MD, FAAP

President, Arkansas Children's Hospital Research Institute

Chairman, Department of Pediatrics

Robert H. Fiser, Jr., M.D. Endowed Chair in Pediatrics

University of Arkansas for Medical Sciences, College of Medicine

Pediatric Infectious Diseases, Arkansas Children’s Hospital

Phone: (501) 364-7373

Research Overview

Dr. Jacobs serves Arkansas Children's Hospital Research Institute not only as its president, but as a researcher as well. He leads research sponsored by the National Institutes of Health’s (NIAID) Collaborative Antiviral Study Group which aims to develop treatments for infectious diseases with no known treatments or where improved treatment regimes are targeted for development. In addition, he is involved in anti-infective pharmacokinetic trials in neonates, infants, and children through NIH-funded (NICHD) Pediatric Pharmacology Research Unit (PPRU). The PPRU, directed by Laura James, MD, conducts carefully controlled clinical trials to establish safety and effectiveness of many medications commonly used to treat a variety of childhood illnesses. Dr. Jacobs joined University of Arkansas for Medical Sciences College of Medicine and Arkansas Children's Hospital in 1982.

Key Publications

Blake MJ, Abdel-Rahman SM, Jacobs RF, Lowery NK, Kearns GL: Pharmacokinetcs of Rifapentine in Children. Pediatr Infect Dis J 25: 405-409, 2006

Buckingham SC, Marshall GS, Schutze GE, Woods CR, Jackson MA, Patterson LE, Jacobs RF: Clinical and Laboratory Features of Rocky Mountain Spotted Fever in Children. J Pediatr 150: 180-184, 2007

Rubino CM, Capparelli EV, Bradley JS, Blumer JL, Kearns GL, Reeds M, Jacobs RF: Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients. Antimicrob Agents Chemotherp 51:1246-1252, 2007

Schutze GE, Buckingham SC, Marshall GS, Woods, CR, Jackson MA, Patterson LE, Jacobs RF: Human Monocytic Ehrlichiosis in Children. Pediatr Infect Dis J 26:475-479, 2007

Abdel-Rahman SM, Benziger DP, Jacobs RF, et al: Single-dose Pharmacokinetics of Daptomycin in Children with Suspected or Proved Gram-Positive Infections. Pediatr Infect Dis J 27:330-334, 2008

Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008 Mar 15;197(6):836-45.

*To find additional publications by this author, please visit Pubmed Central, a National Institutes of Health-operated site for electronic distribution of life sciences research reports.

Research Support

The Horace C. Cabe Foundation

NIH/NIAID Collaborative Anti-viral Study Group

NIH/NICHD Pediatric Pharmacology Research Unit